joel12 schreef op 20 juni 2019 02:44:
the company for 1 reason or another keeps the price low for now. the main issue it had was not the DB which is still ongoing and the market for it its not big and does have also a big threat from CRISPr , gene therapy.
the main issue was the safety of the opthamological drug creating cataracts. AND this was given very strong explanation as to why and also competitively in the latest JMP presentation. I feel ever more comfindent about the safety and future of the ophtamological franchise.
many or most small mid cap biotech stocks have gone down in the past mohths, many without any bad news of any kind. as we move towards XBI 90 and beyond they will recover and I hope PRQR as well. the low share price for an intermediate period hope was used by the company to hire good employees and for its big shareholders to consolidate the positions.
Lastly in fall they are faced with a big event! the phase1/2 data.. which runs parallel to phase3. very important for the data to be good. i wonder if they will manage risk by partnering before this event to get money, or raise further capital.